Gathering the record
Relay is organizing the evidence and source boundaries.
GLP-1/GIP/glucagon triple-agonist peptide
UBT251 is an investigational once-weekly peptide designed to activate GLP-1, GIP, and glucagon receptors.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
UBT251 is an investigational peptide designed to influence three metabolic hormone signals involved in appetite, blood sugar, and energy use.
Researchers are testing the compound across obesity, type 2 diabetes, fatty-liver disease, kidney questions, and drug-interaction studies. Its three-signal design is intended to address several parts of metabolic disease at once.
Relay's independently verifiable record currently contains registered Phase 2 and Phase 3 study designs, but not a complete peer-reviewed pivotal outcome paper. Registration shows what researchers plan to test; it does not demonstrate benefit.
Confirmed efficacy, durability, cardiovascular outcomes, body-composition effects, uncommon harms, completed Phase 3 safety, and regulatory review all remain unresolved. No approved product or transferable preparation standard exists.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Official trial registries describe Phase 2 and Phase 3 studies in adults with obesity or overweight, but Relay's verified record does not yet contain posted pivotal outcomes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Active human development with registry and sponsor-reported evidence; pivotal peer-reviewed outcome evidence remains incomplete.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Confirmed Phase 3 efficacy, durability, cardiovascular outcomes, lean-mass effects, uncommon harms, and regulatory review.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A registered study describes planned research and cannot establish efficacy or safety. No numerical administration pattern, approved product, or generic-vial preparation claim is published here without a complete primary record. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Phase 2 studies are registered and a Phase 3 obesity program is active; Relay does not treat sponsor toplines as equivalent to a complete peer-reviewed pivotal publication.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Confirmed Phase 3 efficacy, durability, cardiovascular outcomes, lean-mass effects, uncommon harms, and regulatory review.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Regulatory and identity status determine how the evidence should be interpreted.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Mechanisms
Registered programs span obesity, type 2 diabetes, MASH, kidney disease, and drug-interaction questions. Sponsor toplines and registry entries must remain separate from peer-reviewed outcome reports.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Registered interventional trial
Adults with overweight or obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with overweight or obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with MASH
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with type 2 diabetes
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Safety snapshot
Pivotal safety is not yet established; gastrointestinal, gallbladder, pancreatic, heart-rate, glucose, lean-mass, and glucagon-pathway questions require complete trial reporting.
Registered study — no resultsReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryInvestigational; active Phase 2 and Phase 3 programs, no FDA approval. Confirmed Phase 3 efficacy, durability, cardiovascular outcomes, lean-mass effects, uncommon harms, and regulatory review.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
NCT07177469
NCT07648225
NCT07145151
NCT07668388